LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

LLY

902.74

-0.9%↓

UNH

596.8

+0.31%↑

NVO

131.05

+0.18%↑

JNJ

164.37

-0.29%↓

ABBV

193.18

+0.34%↑

Начало・Списък с акции・Omeros Corp

Omeros Corp

Затворен

Сектор Здравеопазване

3.64 -7.38

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

3.63

Максимум

3.72

Ключови измерители
By Trading Economics
Приходи	-18M -56M
EPS	-0.15
EBITDA	-48M

Дивиденти
By Dow Jones
Следващи печалби	7.11.2024 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-9.5M 216M
Предишно отваряне	11.02
Предишно затваряне	3.64

Настроения в новините

By Acuity

62%

38%

300 / 365 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

N/A / 3.95 Подкрепа & съпротива

Omeros Corp Графика

Свързани новини

6.09.2024 г., 22:41 ч. UTC

Пазарно говорене

KinderCare and StandardAero File for IPOs -- Market Talk

6.09.2024 г., 21:18 ч. UTC

Топ новини

Hiring Softened This Summer, Teeing Up Fed Rate Cuts -- Update

6.09.2024 г., 21:05 ч. UTC

Топ новини

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- 4th Update

6.09.2024 г., 20:50 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

6.09.2024 г., 20:39 ч. UTC

Печалби

Update: NIO Stock Caught an Upgrade. Shares Rose. -- Barrons.com

6.09.2024 г., 20:35 ч. UTC

Топ новини

Stocks Extend Ugly Week of Losses Amid Economic Uncertainty -- WSJ

6.09.2024 г., 20:34 ч. UTC

Топ новини

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- 3rd Update

6.09.2024 г., 20:11 ч. UTC

Топ новини

Stock Indexes Close Lower After Mixed Jobs Report -- WSJ

6.09.2024 г., 19:51 ч. UTC

Топ новини

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- WSJ

6.09.2024 г., 19:16 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Hold Gains -- Market Talk

6.09.2024 г., 19:14 ч. UTC

Пазарно говорене

Oil Futures Extend Losses on Demand Concerns -- Market Talk

6.09.2024 г., 19:01 ч. UTC

Пазарно говорене

Gold Slips on Prevailing Uncertainty -- Market Talk

6.09.2024 г., 18:27 ч. UTC

Топ новини

JPMorgan Plans to Report Customers Who Exploited TikTok 'Glitch' to Authorities -- WSJ

6.09.2024 г., 18:25 ч. UTC

Пазарно говорене

Broadcom Growth Views Conservative Amid AI Investments -- Market Talk

6.09.2024 г., 18:15 ч. UTC

Топ новини

U.S. Tells Allies Iran Has Sent Ballistic Missiles to Russia, European and U.S. Officials Say -- Update

6.09.2024 г., 18:12 ч. UTC

Топ новини

Nasdaq Falls 2.5%, Leads Losses After Mixed Jobs Report -- WSJ

6.09.2024 г., 17:44 ч. UTC

Пазарно говорене

Labor Costs Represent Diminishing Risk To Canada CPI, CIBC's Shenfeld Says -- Market Talk

6.09.2024 г., 17:30 ч. UTC

Пазарно говорене

U.S Oil Rig Count Unchanged at 483 -- Market Talk

6.09.2024 г., 17:30 ч. UTC

Топ новини

Boeing's Starliner Is Returning to Earth Without Its Crew -- WSJ

6.09.2024 г., 17:27 ч. UTC

Топ новини

Hiring Softened This Summer, Teeing Up Fed Rate Cuts -- WSJ

6.09.2024 г., 17:00 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

6.09.2024 г., 17:00 ч. UTC

Пазарно говорене

Mexican Inflation Seen Easing in August -- Market Talk

6.09.2024 г., 16:36 ч. UTC

Пазарно говорене

Oil Futures Fall as U.S. Jobs Report Sinks In -- Market Talk

6.09.2024 г., 16:35 ч. UTC

Печалби

Горещи акции

Stocks to Watch Friday: Broadcom, Nvidia, UiPath, Smith & Wesson -- WSJ

6.09.2024 г., 16:33 ч. UTC

Придобивния, сливания и поглъщания

Salesforce Stock Is on Pace for Longest Losing Streak Since 2008. An Acquisition Isn't Helping. -- Barrons.com

6.09.2024 г., 16:20 ч. UTC

Пазарно говорене

Печалби

Tech, Media & Telecom Roundup: Market Talk

6.09.2024 г., 16:20 ч. UTC

Печалби

Oracle Profit, Revenue Set to Rise in 1Q -- Earnings Preview

6.09.2024 г., 16:20 ч. UTC

Пазарно говорене

Auto & Transport Roundup: Market Talk

6.09.2024 г., 16:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

6.09.2024 г., 16:20 ч. UTC

Пазарно говорене

Energy & Utilities Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

Omeros Corp Прогноза

Консенсусна оценка

By TipRanks

Неутрален

1 ratings

Купи

Задържане

Продай

Според 1 анализатори, дали борсови рейтинги на Omeros Corp през последните 3 месеца.

Техническа оценка

By Trading Central

N/A / 3.95Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Настроение

By Acuity

300 / 365 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Omeros Corp

Omeros Corporation is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers. Its lead drug product OMIDRIA (phenylephrine and ketorolac intraocular solution) is used during cataract surgery or intraocular lens replacement for adult and pediatric patients. Its drug candidate narsoplimab is the subject of a biologics license application (BLA) for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). It also has multiple Phase III and Phase II clinical-stage development programs in its pipeline, which are focused on complement-mediated disorders, including immunoglobulin A (IgA) nephropathy, atypical hemolytic uremic syndrome (aHUS) and COVID-19.